NCT02534649 Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials
| NCT ID | NCT02534649 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Bergonié |
| Condition | Solid Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2015-12 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10,000 participants in total. It began in 2015-12 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease. In this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling. Patients included in the BIP study and for whom a targetable genomic alteration had been identified might be subsequently included in an early phase trials running at Institut Bergonie or another French hospital.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years, 2. Histology: solid malignant tumor or hematological malignancy, 3. Deleted MSA9 4. Deleted MSA9, 5. Deleted MSA9, 6. Deleted MSA9, 7. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code), 8. Voluntary signed and dated written informed consent prior to any study specific procedure. Exclusion Criteria: 1. Deleted MSA9 2. Deleted MSA9 3. Deleted MSA9 4. Deleted MSA9 5. Deleted MSA9 6. Deleted MSA9 7. Deleted MSA9 8. Deleted MSA9 9. Individuals deprived of liberty or placed under guardianship 10. Pregnant or breast feeding women, 11. Previous enrolment in the present study.
Contact & Investigator
Antoine ITALIANO, MD, PhD
✉ a.italiano@bordeaux.unicancer.frAntoine ITALIANO, MD, PhD
STUDY CHAIR
Institut Bergonié
Frequently Asked Questions
Who can join the NCT02534649 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02534649 currently recruiting?
Yes, NCT02534649 is actively recruiting participants. Contact the research team at a.italiano@bordeaux.unicancer.fr for enrollment information.
Where is the NCT02534649 trial being conducted?
This trial is being conducted at Bayonne, France, Bordeaux, France, Bordeaux, France, Bordeaux, France and 3 additional locations.
Who is sponsoring the NCT02534649 clinical trial?
NCT02534649 is sponsored by Institut Bergonié. The principal investigator is Antoine ITALIANO, MD, PhD at Institut Bergonié. The trial plans to enroll 10,000 participants.